Researchers have identified a novel form of pathological protein aggregation that may play a significant role in the progression of Alzheimer’s disease, shedding new light on the mechanisms underlying neurodegeneration and opening the door to potential new treatment strategies.

The study focuses on the protein G-protein-coupled receptor kinase 2 (GRK2), a critical regulator of cellular growth, survival, and signaling. Investigators discovered that an abnormal, phosphorylated form of the protein—known as phospho-S670-GRK2—accumulates and aggregates in the brains of both Alzheimer’s disease mouse models and patients diagnosed with dementia consistent with Alzheimer’s disease.

The findings suggest that this pathological aggregation may contribute directly to mitochondrial dysfunction, neuronal damage, and disease progression.

A New Layer in Alzheimer’s Disease Pathology

For decades, Alzheimer’s disease research has centered on the accumulation of beta-amyloid plaques and tau neurofibrillary tangles, the two hallmark pathological features of the disease. While these protein aggregates are widely believed to drive neurodegeneration, therapies designed to remove beta-amyloid have produced only modest clinical benefits, prompting researchers to investigate additional mechanisms involved in disease progression.

The new study indicates that beta-amyloid and disease-associated tau proteins may trigger the formation of phospho-S670-GRK2 aggregates. Specifically, researchers found that exposure to beta-amyloid and the neurofibrillary-tangle-inducing mutant TAU-P301L protein promoted harmful GRK2 aggregation.

Once formed, these GRK2 aggregates appear to initiate a cascade of cellular dysfunction.

Mitochondrial Damage and Amplification of Disease Processes

According to the researchers, aggregated phospho-S670-GRK2 induces the aggregation of TOMM6, a key component of the translocase of the outer mitochondrial membrane complex responsible for transporting proteins into mitochondria.

The resulting TOMM6 dysfunction impairs mitochondrial performance, reducing the ability of neurons to generate energy efficiently and maintain cellular health. Mitochondrial dysfunction has long been recognized as a hallmark of aging and neurodegenerative diseases, including Alzheimer’s disease.

Importantly, the study found that GRK2 aggregation not only damages mitochondria but also appears to promote additional beta-amyloid accumulation, potentially creating a self-reinforcing cycle that accelerates neurodegeneration.

Experimental Interventions Demonstrate Therapeutic Potential

To determine whether GRK2 aggregation contributes directly to disease pathology, researchers employed several experimental strategies in animal models.

The team demonstrated that transgenic expression of an inactive form of GRK2, known as GRK2-K220R, as well as administration of a GRK-inhibitory peptide, reproduced key neuropathological features of Alzheimer’s disease. These findings support the conclusion that loss of normal GRK2 function contributes significantly to neuronal damage.

Researchers also explored whether restoring mitochondrial function through TOMM6 replacement could counteract disease progression. While neuron-specific expression of TOMM6 successfully reduced beta-amyloid plaque burden, it unexpectedly increased levels of soluble beta-amyloid and was associated with higher mortality rates, highlighting the complexity of manipulating downstream disease pathways.

More encouraging results emerged from approaches aimed directly at restoring healthy GRK2 activity. Reconstitution of monomeric, functional GRK2 and the selective degradation of aggregated phospho-S670-GRK2 using small-molecule compounds significantly reduced Alzheimer’s-related neuropathology in experimental models. These interventions prevented neuronal loss, improved survival outcomes, and mitigated several key features of disease progression.

Implications for Future Alzheimer’s Therapies

The findings position pathological GRK2 aggregation as a potentially important contributor to age-related neurodegeneration and Alzheimer’s disease. While additional studies are needed to determine whether GRK2 aggregation is primarily a downstream consequence of beta-amyloid and tau pathology or an independent driver of disease, the results suggest that targeting GRK2 may offer therapeutic benefits beyond those achieved through amyloid-focused approaches alone.

By identifying a new link between protein aggregation, mitochondrial dysfunction, and neuronal loss, the research expands the current understanding of Alzheimer’s disease biology and highlights novel opportunities for intervention.

As scientists continue to search for more effective treatments for Alzheimer’s disease, strategies aimed at preventing GRK2 aggregation or restoring normal GRK2 function may represent a promising avenue for slowing neurodegeneration, preserving neuronal health, and improving patient outcomes.